Navigation Links
Premier Research Announces Milestone New Drug Application
Date:3/4/2009

PHILADELPHIA, March 4 /PRNewswire/ -- Premier Research Group Limited, the international pharmaceutical services group, is pleased to announce its role in the submission of the New Drug Application for Acurox(R) (Oxycodone HCl/niacin) Tablets for the sponsor, Acura Pharmaceuticals. Premier Research provided full service clinical trial management for the pivotal Phase 3 clinical safety and efficacy study, which was conducted at their research centers, as well as provided the programming, data management, statistics, medical writing, regulatory strategy and FDA liaison for the NDA. Ron Spivey, Ph.D., Acura's Senior Vice President and Chief Scientific Officer responsible for the NDA submission remarked, "I have truly enjoyed working with the entire Premier Research group. This organization is the best CRO I have ever worked with."

"The ability of a pharmaceutical company to outsource both the clinical development and regulatory submission to a single CRO provides significant internal synergies to our clients. Moreover, our team exceeded client expectations for quality and timeliness of this submission, a true testament to the extraordinary talent and experience that exists within Premier Research. We are very proud of this accomplishment and our people," commented Dr. Troy McCall, Chief Operating Officer.

Acurox(R), a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient, has a proposed indication for the relief of moderate to severe pain. Acurox(R) utilizes Acura Pharmaceuticals' patented Aversion(R) Technology, which is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of dissolved tablets and nasal snorting of crushed tablets.

The submission of the NDA for Acurox(R) Tablets adds to considerable and growing expertise of the company in the analgesic therapeutic area. James Otti
'/>"/>

SOURCE Premier Research Group Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Premier Micronutrient Launches Supplement for Hearing Health
2. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
3. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
4. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
9. Video: New Research Discovers Independent Brain Networks Control Human Walking
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...4 Oxygen Biotherapeutics...that the first patient has been enrolled in the co...l in Switzerland for use of Oxycyte(TM) emulsion i...pany,s perfluorocarbon (PFC) therapeutic oxygen ca...ce in improving the outcome of patients with sever...
(Date:12/4/2009)...Dec. 4 Shared Imaging, LLC, an ind...d service programs for hospitals and healthcare pr...e Joint Commission,s Accreditation for Ambulatory ...gold seal of approval for quality and safety in pa...-wide for its mobile MRI and PET/CT services. Mobi...
(Date:12/4/2009)...NGTON, Dec. 4 Chemistr...shed by the Pharmaceutical Research and Manufactu...drugs and vaccines in development for HIV/AIDS and...hat the 97 products in development include 23 vacc...human clinical trials or awaiting approval by the ...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 58794 1Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 58794 2Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick Maryland 14340 1Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick Maryland 14340 2Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick Maryland 14340 3Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick Maryland 14340 4Personalized Medicine Killer Apps Will Transform Care Model 5199 1Personalized Medicine Killer Apps Will Transform Care Model 5199 2
...eek Buyer for Marketed Parenteral Product Ganite(R...orated,(Nasdaq: GNTA ) today announced that the C...tion covering novel pharmaceutical gallium composi...atent Office. Issued U.S.,Patent 7,354,952 extends...,s franchise of oral gallium-containing products t...
...port Gene-Silencing Mechanism and Demonstrate Sign...tiple Tumor Models in Mice, PALO ALTO, Calif., Ap... of targeted, systemic RNA interference (RNAi),the...nstrated the company,s,RNAi Nanoplex (NPX) deliver...livering small interfering RNAs (siRNAs) targeting...
Other Medicine Technology:Genta Receives Key Patent Related to Oral Gallium Compound G4544 2Genta Receives Key Patent Related to Oral Gallium Compound G4544 3Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models 2Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models 3
(Date:12/4/2009)...w study shows that muscle cells grown in the lab c...properly. The work, performed in dogs and rats, mi... such as gastric reflux and fecal incontinence. ,...ers, which are the bands of muscle that separate t...ss in these areas can cause gastrointestinal esoph...
(Date:12/4/2009)...t men can be bastards and women must wear pearls a...nswer, according to an article in the Journal of ...xpressions. , In two studies, researchers asked ... In the first study, androgynous faces with lowere... more likely to be identified as male, and faces w...
(Date:12/4/2009)... federal regulators to crack down on abuse of opio...hDay News) -- The makers of 24 different prescript...tors with plans to curb the abuse of these opioid ...n under pressure from U.S. Food and Drug Administr... of fatal overdoses that occur with these medicati...
(Date:12/4/2009)... back during winter isn,t known, CDC says, , ...ber of states reporting widespread swine flu activ... high of 48 just two weeks ago, a U.S. health offi...N1 swine flu vaccine continues to increase, Dr. Th...Disease Control and Prevention, said during an aft...
(Date:12/4/2009)...lood vessel growth after heart attack , ,...lls appear to help repair heart attack damage, a n...nts found that stem cells from donor bone marrow p...issue damaged by heart attack. , The patients r... having a heart attack. During follow-up, they wer...
Breaking Medicine News(10 mins):Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Are angry women more like men? 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Swine Flu Continues to Wane 2
...n gum bacteria, scientists had been able to use li...he oral cavity. The dental samples obtained f...were exposed to broadband light (380 to 520nm). Th... light had killed bacteria like Prevotella interme...
... titled Millennium Ecosystem Assessment, scientist...of the world are having a detrimental effect to hu...ears. Diseases such as malaria and cholera ar...ustainable way. The report emphasizes that th...
...at was published in American Journal of Public Hea...s possible to reduce the causes of asthma in child...searchers had identified 274 low-income households...ers used systematic interventions. Some of these i...
...udy conducted by US and Canadian scientists, consu...ked with having breast cancer for women. The...the incidence of breast cancer in 1461 cases, had ...imple carbohydrates and sugars like refined flour,...
...am that had looked into a data comprising of 5461 ...ss physical activity often makes these girls more ...at 16% of the participants take part in vigorous p...oing physical activity for fewer hours per week. T...
... market watchdog Food and Drug Administration had ... the drugs in the class of non-steroidal anti-infl...ription over the counter. These changes include th...rall risk associated with the drug overshadows the...
Other Medicine News:
Renu Rewetting Drops
Lens Plus Sterile Saline Solution
Softwear Saline
Sterile Preserved Saline Solution
Medicine Products: